<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04145258</url>
  </required_header>
  <id_info>
    <org_study_id>ANRS 12398 INTENSE-TBM</org_study_id>
    <secondary_id>EDCTP RIA2017T-2019</secondary_id>
    <nct_id>NCT04145258</nct_id>
  </id_info>
  <brief_title>Intensified Tuberculosis Treatment to Reduce the Mortality of Patients With Tuberculous Meningitis</brief_title>
  <acronym>INTENSE-TBM</acronym>
  <official_title>Intensified Tuberculosis Treatment to Reduce the Mortality of HIV-infected and Uninfected Patients With Tuberculosis Meningitis: a Phase III Randomized Controlled Trial (Acronym: INTENSE-TBM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ANRS, Emerging Infectious Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Union</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European and Developing Countries Clinical Trials Partnership (EDCTP)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ANRS, Emerging Infectious Diseases</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      INTENSE-TBM is randomized controlled, phase III, multicenter, 2 x 2 factorial plan&#xD;
      superiority trial assessing the efficacity of two interventions to reduce mortality from&#xD;
      tuberculous meningitis (TBM) in adolescents and adults with or without HIV-infection in&#xD;
      sub-Saharan Africa:&#xD;
&#xD;
        -  Intensified TBM treatment with high-dose rifampicin and linezolid, compared to WHO&#xD;
           standard TBM treatment.&#xD;
&#xD;
        -  Aspirin, compared to not receiving aspirin. The trial will be open-label for anti-TB&#xD;
           treatment and placebo-controlled for aspirin treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Settings: Côte d'Ivoire, Madagascar, Uganda, South Africa.&#xD;
&#xD;
      Follow-up: Participants will be followed up for 40 weeks.&#xD;
&#xD;
      Sample size: 768 patients (192 in each arm).&#xD;
&#xD;
      Primary analysis: We will use a Cox proportional hazard ratio model to compare intensified TB&#xD;
      treatment with WHO standard TB treatment, and aspirin with placebo, adjusting for the initial&#xD;
      stratification variables (trial country, HIV status, British Medical Research Council |BMRC]&#xD;
      severity grade). The primary analysis will be conducted in the intention to treat population.&#xD;
&#xD;
      Sub-studies:&#xD;
&#xD;
        -  The PK-PD sub-study will take place in the 4 participating countries, and involve 40&#xD;
           participants in total.&#xD;
&#xD;
        -  The Multi-Omics sub-study will only take place in South-Africa. It will involve 160&#xD;
           participants in this country.&#xD;
&#xD;
      Participants in each sub-study will sign a specific informed consent.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 9, 2020</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The trial will be open-label for anti-TB treatment and placebo-controlled for aspirin treatment</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of all-cause death</measure>
    <time_frame>Up to 40 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of all-cause death</measure>
    <time_frame>Up to 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of all-cause death or loss to follow-up</measure>
    <time_frame>Up to 40 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of new central neurological event or aggravation of a central neurological event existing at baseline</measure>
    <time_frame>Up to 40 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of grade 3-4 adverse events (DAIDS adverse events grading table)</measure>
    <time_frame>Up to 40 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of serious adverse events</measure>
    <time_frame>Up to 40 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of solicited treatment related adverse events</measure>
    <time_frame>Up to 40 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with disability</measure>
    <time_frame>40 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>M. tuberculosis culture conversion rate</measure>
    <time_frame>1 week and 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to culture positivity</measure>
    <time_frame>Up to 40 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first hospital discharge</measure>
    <time_frame>Up to 40 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness incremental ratio of trial interventions</measure>
    <time_frame>Up to 40 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of resistance to anti-TB drugs among patients with positive culture at inclusion</measure>
    <time_frame>Up to 40 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subset of patients: In vitro bactericidal activity of anti-TBM treatment</measure>
    <time_frame>1 week and 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subset of patients: Maximum Plasma Concentration [Cmax] of rifampicin and linezolid</measure>
    <time_frame>1 week and 4 weeks</time_frame>
    <description>Plasma Cmax, cerebrospinal fluid [CSF] Cmax, and plasma/CSF Cmax ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subset of patients: Minimum Plasma Concentration [Cmin] of rifampicin and linezolid</measure>
    <time_frame>1 week and 4 weeks</time_frame>
    <description>Plasma Cmin, cerebrospinal fluid [CSF] Cmin, and plasma/CSF Cmin ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subset of patients: Area Under the Curve [AUC] of rifampicin and linezolid</measure>
    <time_frame>1 week and 4 weeks</time_frame>
    <description>Plasma AUC, cerebrospinal fluid [CSF] AUC, and plasma/CSF AUC ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subset of patients: Time for maximal concentration [Tmax] of rifampicin and linezolid</measure>
    <time_frame>1 week and 4 weeks</time_frame>
    <description>Plasma Tmax, cerebrospinal fluid [CSF] Tmax, and plasma/CSF Tmax ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subset of patients: Half-life (t1/2) of rifampicin and linezolid</measure>
    <time_frame>1 week and 4 weeks</time_frame>
    <description>Plasma t1/2, cerebrospinal fluid [CSF] t1/2, and plasma/CSF t1/2 ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV-infected participants: Rate of new AIDS-defining illnesses</measure>
    <time_frame>Up to 40 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV-infected participants: Percentage of participants with virological success (plasma HIV-1 RNA &lt;50 copies/ml)</measure>
    <time_frame>28 weeks and 40 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV-infected participants: CD4 count change from baseline</measure>
    <time_frame>28 weeks and 40 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV-infected participants, subset of patients: Maximum Plasma Concentration [Cmax] of of dolutegravir</measure>
    <time_frame>1 week and 4 weeks</time_frame>
    <description>Plasma Cmax, cerebrospinal fluid [CSF] Cmax, and plasma/CSF Cmax ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV-infected participants, subset of patients: Minimum Plasma Concentration [Cmin] of dolutegravir</measure>
    <time_frame>1 week and 4 weeks</time_frame>
    <description>Plasma Cmin, cerebrospinal fluid [CSF] Cmin, and plasma/CSF Cmin ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV-infected participants, subset of patients: Area Under the Curve [AUC] of dolutegravir</measure>
    <time_frame>1 week and 4 weeks</time_frame>
    <description>Plasma AUC, cerebrospinal fluid [CSF] AUC, and plasma /CSF AUC ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV-infected participants, subset of patients: Time for maximal concentration [Tmax] of dolutegravir</measure>
    <time_frame>1 week and 4 weeks</time_frame>
    <description>Plasma Tmax, cerebrospinal fluid [CSF] Tmax, and plasma /CSF Tmax ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV-infected participants, subset of patients: Half-life (t1/2) of dolutegravir</measure>
    <time_frame>1 week and 4 weeks</time_frame>
    <description>Plasma t1/2, cerebrospinal fluid [CSF] t1/2, and plasma/CSF t1/2 ratio</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">768</enrollment>
  <condition>Tuberculous Meningitis</condition>
  <arm_group>
    <arm_group_label>WHO TBM treatment + placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Inclusion (D-0) to end of Week-8 (W-8): isoniazid 5 mg/kg/d + rifampicin 10 mg/kg/d + ethambutol 20 mg/kg/d + pyrazinamide 30 mg/kg/d + placebo of aspirin&#xD;
W-9 to W-40: isoniazid 5 mg/kg/d + rifampicin 10 mg/kg/d.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>WHO TBM treatment + aspirin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Inclusion (D-0) to end of Week-8 (W-8): isoniazid 5 mg/kg/d + rifampicin 10 mg/kg/d + ethambutol 20 mg/kg/d + pyrazinamide 30 mg/kg/d + aspirin 200 mg/d&#xD;
W-9 to W-40: isoniazid 5 mg/kg/d + rifampicin 10 mg/kg/d.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intensified TBM treatment + placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Inclusion (D-0) to end of Week-8 (W-8): high dose rifampicin (35 mg/kg/d) + high dose linezolid (1200 mg/d from D-0 to end of W-4, then 600 mg/d from W-5 to W-8) + isoniazid 5 mg/kg/d + ethambutol 20 mg/kg/d + pyrazinamide 30 mg/kg/d + placebo of aspirin&#xD;
W-9 to W-40: isoniazid 5 mg/kg/d + rifampicin 10 mg/kg/d.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intensified TBM treatment + aspirin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Inclusion (D-0) to end of Week-8 (W-8): high dose rifampicin (35 mg/kg/d) + high dose linezolid (1200 mg/d from D-0 to end of W-4, then 600 mg/d from W-5 to W-8) + isoniazid 5 mg/kg/d + ethambutol 20 mg/kg/d + pyrazinamide 30 mg/kg/d + aspirin 200 mg/d&#xD;
W-9 to W-40: isoniazid 5 mg/kg/d + rifampicin 10 mg/kg/d.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Two tablets of aspirin 100 mg per day from inclusion (D-0) to end of Week-8 (W-8)</description>
    <arm_group_label>Intensified TBM treatment + aspirin</arm_group_label>
    <arm_group_label>WHO TBM treatment + aspirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo of aspirin</intervention_name>
    <description>Two placebo tablets with the same appearance of aspirin 100 mg per day from inclusion (D-0) to end of Week-8 (W-8)</description>
    <arm_group_label>Intensified TBM treatment + placebo</arm_group_label>
    <arm_group_label>WHO TBM treatment + placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>WHO TBM treatment</intervention_name>
    <description>2 months of (R-H-Z-E) + 7 months of (R-H)</description>
    <arm_group_label>WHO TBM treatment + aspirin</arm_group_label>
    <arm_group_label>WHO TBM treatment + placebo</arm_group_label>
    <other_name>Standard WHO treatment for TB meningitis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intensified TBM treatment</intervention_name>
    <description>2 months of (HDR-L-H-Z-E) + 7 months of (R-H), with HDR=high-dose rifampicin and L=linezolid</description>
    <arm_group_label>Intensified TBM treatment + aspirin</arm_group_label>
    <arm_group_label>Intensified TBM treatment + placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. Age ≥ 15 years&#xD;
&#xD;
          2. TBM defined as &quot;definite&quot;, &quot;probable&quot; or &quot;possible&quot;&#xD;
&#xD;
          3. Signed Informed Consent&#xD;
&#xD;
               -  Definite TBM = at least one of the following criteria: acid-fast bacilli seen in&#xD;
                  CSF microscopy, positive CSF M. tuberculosis culture, or positive CSF M.&#xD;
                  tuberculosis commercial nucleic acid amplification test.&#xD;
&#xD;
               -  Probable TBM = total modified Marais score ≥12 when neuroimaging is available, or&#xD;
                  ≥10 when neuroimaging is not available (at least 2 points should come from CSF or&#xD;
                  cerebral imaging criteria).&#xD;
&#xD;
               -  Possible TBM = total modified Marais 6-11 when neuroimaging is available, or 6-9&#xD;
                  when neuroimaging is not available.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  &gt; 5 days of TB treatment&#xD;
&#xD;
          -  Renal failure (eGFR&lt;30 ml/min, CKD-EPI formula).&#xD;
&#xD;
          -  Neutrophil count &lt; 0.6 x 109/L.&#xD;
&#xD;
          -  Hemoglobin concentration &lt; 8 g/dL.&#xD;
&#xD;
          -  Platelet count &lt; 50 x 109/L.&#xD;
&#xD;
          -  Total bilirubin &gt; 2.6 times the Upper Limit of Normal.&#xD;
&#xD;
          -  ALT &gt; 5 times the Upper Limit of Normal.&#xD;
&#xD;
          -  Clinical evidence of liver failure or decompensated cirrhosis.&#xD;
&#xD;
          -  For women: more than 17 weeks pregnancy or breastfeeding.&#xD;
&#xD;
          -  For patients without decrease level of consciousness (Glasgow Coma Scale = 15):&#xD;
             Peripheral neuropathy scoring Grade 3 or above on the Brief Peripheral Neuropathy&#xD;
             Score (BPNS).&#xD;
&#xD;
          -  Documented M. tuberculosis resistance to rifampicin.&#xD;
&#xD;
          -  Positive gram-stain, bacterial culture or cryptococcal antigen in the Cerebral Spinal&#xD;
             Fluid.&#xD;
&#xD;
          -  Evidence of active bleeding (hemoptysis, gastrointestinal bleeding, hematuria,&#xD;
             intracranial bleeding).&#xD;
&#xD;
          -  Inability to collect Cerebral Spinal Fluid, except for patients with confirmed&#xD;
             tuberculosis (by rapid molecular test or culture) from another biological sample and&#xD;
             clinical and/or CT scan evidence of meningitis.&#xD;
&#xD;
          -  Major surgery within the last two weeks prior to inclusion.&#xD;
&#xD;
          -  Ongoing chronic aspirin treatment (eg for cardiovascular risk).&#xD;
&#xD;
          -  Current use of drugs contraindicated with study drugs and that cannot be safely&#xD;
             stopped (see Appendix 1: Drugs contra-indicated with study drugs).&#xD;
&#xD;
          -  In available history from patients:&#xD;
&#xD;
               -  Evidence of past intracranial bleeding.&#xD;
&#xD;
               -  Evidence of past of peptic ulceration.&#xD;
&#xD;
               -  Evidence of recent (&lt; 3 month) gastrointestinal bleeding.&#xD;
&#xD;
               -  Known hypersensitivity contraindicating the use of study drugs .&#xD;
&#xD;
               -  Evidence of porphyria.&#xD;
&#xD;
               -  Evidence of hyperuricemia or gout.&#xD;
&#xD;
          -  Any reason which at the discretion of the investigator would compromise safety and&#xD;
             cooperation in the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabrice Bonnet, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fabrice Bonnet, M.D., Ph.D.</last_name>
    <phone>+33 (0)5 56 79 58 26</phone>
    <email>fabrice.bonnet@chu-bordeaux.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xavier Anglaret, M.D., Ph.D.</last_name>
    <phone>+33 (0)5 57 57 12 58</phone>
    <email>xavier.anglaret@u-bordeaux.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cocody University Hospital</name>
      <address>
        <city>Abidjan</city>
        <country>Côte D'Ivoire</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Horo Kigninlman, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Treichville University Hospital</name>
      <address>
        <city>Abidjan</city>
        <country>Côte D'Ivoire</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gisèle Kouakou, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yopougon University Hospital</name>
      <address>
        <city>Abidjan</city>
        <country>Côte D'Ivoire</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thierry Odehoury-Koudou, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Joseph Raseta Befelatanana</name>
      <address>
        <city>Antananarivo</city>
        <country>Madagascar</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mamy Jean de Dieu Randria, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Tambohobe</name>
      <address>
        <city>Fianarantsoa</city>
        <country>Madagascar</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rivonirina Andry Rakotoarivelo, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Morafeno</name>
      <address>
        <city>Toamasina</city>
        <country>Madagascar</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stéphane Dimby Ralandison, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Groote Schuur Hospital</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robert J Wilkinson, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mitchells Plain Hospital</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Graeme Meintjes, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>New Somerset Hospital</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sean Wassermann, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dora Nginza Hospital</name>
      <address>
        <city>Port Elizabeth</city>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Livingstone and PE Central Hospitals</name>
      <address>
        <city>Port Elizabeth</city>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>John Black, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mbarara Regional Reference Hospital</name>
      <address>
        <city>Mbarara</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Conrad Muzoora, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Regional Reference Hospital of Kabale</name>
      <address>
        <city>Mbarara</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marion Namutebi, Dr.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Côte D'Ivoire</country>
    <country>Madagascar</country>
    <country>South Africa</country>
    <country>Uganda</country>
  </location_countries>
  <link>
    <url>https://intense-tbm.org/</url>
    <description>INTENSE-TBM project website</description>
  </link>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>October 22, 2019</study_first_submitted>
  <study_first_submitted_qc>October 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2019</study_first_posted>
  <last_update_submitted>February 11, 2021</last_update_submitted>
  <last_update_submitted_qc>February 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tuberculous Meningitis</keyword>
  <keyword>Intensified treatment</keyword>
  <keyword>High dose Rifampicin</keyword>
  <keyword>Linezolid</keyword>
  <keyword>Aspirin</keyword>
  <keyword>Subsaharan Africa</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Meningeal</mesh_term>
    <mesh_term>Meningitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

